CA - Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

2024-04-12 14:12:23 ET

Summary

• Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024.
• In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%.
• Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.
• Zentalis received an upfront payment of $35 million and is eligible to earn up to $275 million payments in milestones plus royalties after out-licensing its ROR1 ADC to Immunome.

Zentalis Pharmaceuticals, Inc. ( ZNTL ) is working on advancing its lead candidate in its pipeline known as azenosertib as both a monotherapy and in combination with other drugs for the treatment of patients with solid tumor and hematological malignancies. One of its most advanced programs would be the use of this drug as a monotherapy for the treatment of patients with platinum resistant high-grade serous ovarian cancer in the ongoing phase 2 Denali or ZN-c3-005 study. Top-line results from this study are expected to be released in the 1st half of 2025....

For further details see: